Patents Assigned to Eli Lilly and Company Patent Division
-
Publication number: 20090118167Abstract: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.Type: ApplicationFiled: August 11, 2005Publication date: May 7, 2009Applicant: Eli Lilly and Company Patent DivisionInventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
-
Publication number: 20080213281Abstract: The invention provides a butyrylchinesterase variant, a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant and a method of treating cancer by administering to an individual an effective amount a butyrylcholinesterase variant exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.Type: ApplicationFiled: December 4, 2003Publication date: September 4, 2008Applicant: Applied Molecular Evolution, Inc. c/o Eli Lilly and Company Patent DivisionInventors: Jeffrey D. Watkins, James D. Pancock
-
Publication number: 20080207716Abstract: The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 ?g or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit.Type: ApplicationFiled: January 25, 2006Publication date: August 28, 2008Applicant: Eli Lilly and Company Patent DivisionInventors: Eyas Jamal Abu-Raddad, Michael Arthur Derby, Cynthia Joyce Harris, Daniel Charles Howey, Laura Frey Michael
-
Publication number: 20070249623Abstract: 1-(Indole-6-carbonyl-D-phenylglycinyl)-4-(1-methyl-piperidin-4-yl)piperazine D-tartrate forms a stable crystalline salt and is an inhibitor of the serine protease, Factor Xa, useful in the treatment of cardiovascular disorders.Type: ApplicationFiled: June 13, 2005Publication date: October 25, 2007Applicant: Eli Lilly and Company Patent DivisionInventor: Julie Bush
-
Publication number: 20070105845Abstract: This invention relates to compounds of formula (I) where —X—, n, R1, R3 and Ar— have the values defined herein, their preparation, and use as pharmaceuticals.Type: ApplicationFiled: April 15, 2004Publication date: May 10, 2007Applicant: Eli Lilly and Company Patent DivisionInventors: Nicholas Camp, Roberta Penariol, Christopher Beadle
-
Publication number: 20070088288Abstract: A guide and follower cooperate to promote a user moving the driver relative to the housing along a travel path that operates the apparatus. The cooperating elements of the nut and the driver are disengaged when the driver is disposed in a reset segment of the travel path, and the cooperating elements of the nut and the driver become engaged when the driver is shifted through a nut engaging segment of the travel path from the reset segment to a nut rotating segment of the travel path. The engagement of the cooperating elements of the nut and the driver cause the nut to screw proximally along the threaded shaft of the drive member when the driver is shifted through the nut rotating segment from the nut engaging segment to an injecting section of the travel path.Type: ApplicationFiled: October 15, 2004Publication date: April 19, 2007Applicant: Eli Lilly and Company Patent DivisionInventors: Traci Barron, Andrew Burroughs, David Hixson
-
Publication number: 20070078166Abstract: The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof.Type: ApplicationFiled: October 12, 2004Publication date: April 5, 2007Applicant: Eli Lilly and Company Patent DivisionInventors: Alfio Borghese, David Coffey, Pamela Footman, Steven Pedersen, Susan Reutzel-Edens, Shella Tameze, Carsten Timpe, Carsten Weber
-
Publication number: 20070010558Abstract: A compound of the formula (I) wherein the variables X1 to X5, R1 to R7 including R3?, E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.Type: ApplicationFiled: December 6, 2004Publication date: January 11, 2007Applicant: ELI LILLY AND COMPANY Patent DivisionInventors: Dana Benesh, Maria-Jesus Blanco-Pillado
-
Publication number: 20060293223Abstract: The present invention provides methods of treating metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, methods of inducing weight loss and increasing muscle mass in a patient, by administration of MC3R agonist peptides. Furthermore, the present invention provides the use of an MC3R agonist peptide for the manufacture of a medicament for the treatment of metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, inducing weight loss and increasing muscle mass in a patient.Type: ApplicationFiled: June 17, 2004Publication date: December 28, 2006Applicant: Eli Lilly and Company Patent DivisionInventors: Robert Gadski, Mark Heiman, Hansen Hsiung, John Mayer, Liang Yan
-
Publication number: 20060211755Abstract: The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C5-C13alkyl; C,—C,2haloalkyl, C4C,2alkenyl, C4-C12alkynyl, or C,—C5alkylcycloalkyl, C3-C8cycloalkyl, C, C5alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with one to three substituents independently selected from C,—C8a)kyl, C,—C8haloalkyl, ?C2-CBalkenyl, C2-C8a)kynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (C}12)m000C,—Csalkyl, (CH2)mNRaRb, and C,C4alkylcycloalkyl; wherein W and Rb are independently selected from hydrogen, C,CBalkyl, C2-CBalkenyl, C2-CBalkynyl, and C,—C5alkylcycloalkyl; R2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,—C12alkyl, C2C,2haloalkyl, C2-C,2 alkenyl, C2-C12alkynyl, C,—C12alkylaryl, C,—C12alkylcyclohexyl, C, C12alkylcyclopentyl, C,—C12alkylheterocyclic, (CH2)m000H, (CH2)mC0(C,—C,o)alkyl, (CH2)m COO(C,—C,o)alkyl, (CH2)mCOO(C1-C,o)alkylaryl, C,—C,oalkylamino, haloType: ApplicationFiled: March 25, 2004Publication date: September 21, 2006Applicant: Eli Lilly and Company Patent DivisionInventors: Patrick Eacho, Patricia Foxworthy-Mason, Ho-Shen Lin, Jose Lopez, Marian Mosior, Michael Richett
-
Publication number: 20060205744Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker, (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4) A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.Type: ApplicationFiled: December 31, 2003Publication date: September 14, 2006Applicant: Eli Lilly and Company Patent DivisionInventors: Scott Conner, Nathan Mantlo, Guoxin Zhu
-
Publication number: 20060167268Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.Type: ApplicationFiled: March 31, 2003Publication date: July 27, 2006Applicant: Eli Lilly and Company, Patent Division,Inventors: Britta Evers, Ruehter Gerd, Eva Martin De La Nava, Mark Tebbe
-
Publication number: 20060167046Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-II3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods or using them to treat obesity and other histamine II3 receptor-related diseases.Type: ApplicationFiled: September 12, 2003Publication date: July 27, 2006Applicant: Eli Lilly and Company Patent DivisionInventors: Lisa Beavers, Don Finley, Robert Gadski, Philip Hipskind, Cynthia Jesudason, Richard Pickard, Freddie Stevens
-
Publication number: 20060084663Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, substituted aryl(C0-C4)alkyl, substituted aryloxy(C0-C4)alkyl, substituted arylthio(C0-C4)alkyl, unsubstituted aryl(C0-C4)alkyl, unsubstituted aryloxy(C0-C4)alkyl, and unsubstituted arylthio(C0-C4)alkyl; (b) T1 is C or N; (c) Q is selected from the group consisting of O, a single bond, O(CH2)q and C; (d) q is 1 or 2; (e) W is selected from the group consisting of O, S, (CH2)rN(R20)(CH2)k, NHSO2, C(O)N(R20)(CH2)r, (CH2)rN(R20)C(O), and SO2; (f) X is CmH2m; (g) m is 0, 1 or 2; (h) A is an functional group selected from the group consisting of carboxyl, C1-C3 alkylnitrile, carboxamide, and (CH2)nCOOR19; and (i) R19 is selected from the group consisting of hydrogen, optionally substituted C1-C4alkyl and optionally substituted arylmethyl.Type: ApplicationFiled: February 13, 2003Publication date: April 20, 2006Applicant: Eli Lilly and Company, Patent DivisionInventors: Scott Conner, Nathan Mantlo, Guoxin Zhu
-
Publication number: 20060079680Abstract: The disclosed invention relates to compounds of the formula (I), and the pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 10, 2003Publication date: April 13, 2006Applicant: Eli Lilly and Company Patent DivisionInventor: Jason Sawyer
-
Publication number: 20050250684Abstract: This invention relates to a novel method of reducing the mortality and morbidity in critically ill patients which comprises administering to the patients an effective amount of FGF-19.Type: ApplicationFiled: September 10, 2003Publication date: November 10, 2005Applicant: Eli Lilly and Company Patent DivisionInventors: Josef Heuer, Alexei Kharitonenkov